3-hydroxy-7-methoxy-2-(3-methylbut-2-en-1-yl)-[1,4]naphthoquinone | 500350-53-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 3-hydroxy-7-methoxy-2-(3-methylbut-2-en-1-yl)-[1,4]naphthoquinone
• 英文别名: 6-methoxylapachol；2-hydroxy-6-methoxy-3-(3-methylbut-2-en-1-yl)-naphthalene-1,4-dione
• CAS: 500350-53-8
• 化学式: C₁₆H₁₆O₄
• 分子量: 272.301
• InChiKey: LYJBPZRSCCLQPB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.24
• 重原子数：
  20.0
• 可旋转键数：
  3.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  63.6
• 氢给体数：
  1.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  3-hydroxy-7-methoxy-2-(3-methylbut-2-en-1-yl)-[1,4]naphthoquinone 在 硫酸 、 氢碘酸 作用下， 以 二氯甲烷 、 溶剂黄146 为溶剂， 反应 3.0h， 生成 9-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[h]chromene
  参考文献：
  名称：

  Lawsone萘醌衍生物的合成、表征及抗白血病特性

  摘要：

  萘醌被认为是抗癌药物分子的特殊结构。2-羟基-1,4-萘醌（劳松）与 1-溴-3-甲基-2-丁烯的赫克反应提供了容易获得拉帕酚的途径。几种天然存在的线性和角杂环醌类化合物（α-lapachone、β-lapachone、dunnione 和相关类似物）由拉帕酚制备。此外，我们证明合成萘醌可抑制人白血病 HL-60 细胞的细胞增殖。特别是，角型衍生物被发现具有中等的细胞毒性并提高细胞内谷胱甘肽二硫化物（GSSG）的水平。我们的工作突出了天然存在的角系列萘醌作为抗白血病药物的巨大潜力。

  DOI：

  10.1002/cmdc.201500189
• 作为产物：
  描述：

  6-甲氧基-1-萘满酮 在 potassium tert-butylate 、 氧气 、 lithium hydride 作用下， 以 二甲基亚砜 、 叔丁醇 为溶剂， 反应 13.5h， 生成 3-hydroxy-7-methoxy-2-(3-methylbut-2-en-1-yl)-[1,4]naphthoquinone
  参考文献：
  名称：

  Identification of β-Lapachone Analogs as Novel MALT1 Inhibitors To Treat an Aggressive Subtype of Diffuse Large B-Cell Lymphoma

  摘要：

  The treatment of activated B cell-like DLBCL (ABC-DLBCL) is one of the urgent unmet medical needs because it is the most resistant DLBCL subtype to current therapies eagerly awaiting effective therapeutic strategies. Recently, the paracaspase MALT1 has emerged as a promising therapeutic target for the treatment of ABC-DLBCL. Herein, we report a new class of MALT1 inhibitors developed by high-throughput screening and structure-based drug design. The original hit, 4-amino-1,2-naphthoquinone series inhibited MALT1 activity but suffered from poor cellular activity. The extensive pharmacophore search led to the discovery of structurally similar beta-lapachone that is a direct inhibitor of MALT1 and possesses favorable physicochemical properties. Molecular simulation studies suggested the possibility of the formation of a covalent bond between MALT1 and, beta-lapachone, which was corroborated by experimental wash-out studies. Inspired by this, we explored the structure activity relationships by incorporating electron-withdrawing substituents at C8 position of beta-lapachone. These MALT1 inhibitors exhibited potent antiproliferative activity to OCI-LY3 cell line and inhibited the cleavage of CYLD mediated MALT1.

  DOI：

  10.1021/acs.jmedchem.5b01415

文献信息

• Synthetic methods for the preparation of ARQ 501 (β-Lapachone) human blood metabolites
  作者：Rui-Yang Yang、Darin Kizer、Hui Wu、Erika Volckova、Xiu-Sheng Miao、Syed M. Ali、Manish Tandon、Ronald E. Savage、Thomas C.K. Chan、Mark A. Ashwell

  DOI：10.1016/j.bmc.2008.03.073

  日期：2008.5

  ARQ 501 (3,4-dihydro-2,2-dimethyl-2H-naphthol[1,2-b]pyran-5,6-dione), a synthetic version of beta-Lapachone, is a promising anti-cancer agent currently in multiple Phase II clinical trials. Promising anti-cancer activity was observed in Phase I and Phase II trials. Metabolism by red blood cells of drugs is an understudied area of research and the metabolites arising from oxidative ring opening (M2 and M3), decarbonylation/ ring contraction (M5), and decarbonylation/ oxidation (M4 and M6) of ARQ 501 offer a unique opportunity to provide insight into these metabolic processes. Since these metabolites were not detected in in vitro incubations of ARQ 501 with liver microsomes and were structurally diverse, confirmation by chemical synthesis was considered essential. In this report, we disclose the synthetic routes employed and the characterization of the reference standards for these blood metabolites as well as additional postulated structures, which were not confirmed as metabolites. (C) 2008 Elsevier Ltd. All rights reserved.